Scarica l'app Stockscreener
12.97
2.90%
0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
Wells Fargo & Company MN Acquires 7,785 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Geode Capital Management LLC Has $9.42 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress - ADVFN
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 - Business Wire
Long Term Trading Analysis for (ARCT) - news.stocktradersdaily.com
JPMorgan Chase & Co. Has $4.01 Million Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Research Analysts Set Expectations for ARCT Q1 Earnings - American Banking and Market News
Q1 Earnings Estimate for ARCT Issued By Leerink Partnrs - Defense World
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine (PR Newswire) - Aktiellt
Vanguard Group Inc. Grows Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Can The Upcoming Catalysts Breathe New Life Into Arcturus Therapeutics? - RTTNews
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - MSN
KLP Kapitalforvaltning AS Acquires New Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
HC Wainwright Reiterates Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
High Growth Tech Stocks To Watch In The US April 2025 - simplywall.st
Arcturus Therapeutics (ARCT) Gains FDA Fast Track for Influenza Vaccine - GuruFocus
Arcturus Therapeutics (ARCT) Receives Fast Track Status for Infl - GuruFocus
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation f - GuruFocus
Guggenheim Lowers Price Target for Arcturus Therapeutics (ARCT) Amid Risk Adjustments | ARCT Stock News - GuruFocus
Arcturus wins FDA fast track status for influenza vaccine - MSN
Arcturus wins FDA fast track status for flu shot (ARCT:NASDAQ) - Seeking Alpha
Arcturus Therapeutics Says FDA Granted Fast Track Designation to Potential H5N1 Vaccine - marketscreener.com
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 - Business Wire
Breakthrough: FDA Fast-Tracks Revolutionary mRNA Vaccine Against Deadly H5N1 Pandemic Flu - Stock Titan
Commonwealth Equity Services LLC Reduces Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $59.20 Consensus Price Target from Brokerages - Defense World
(ARCT) Investment Report - news.stocktradersdaily.com
(ARCT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Bank of New York Mellon Corp Sells 22,024 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey
Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet - simplywall.st
Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN
William Blair Issues Pessimistic Outlook for ARCT Earnings - Defense World
(ARCT) Proactive Strategies - news.stocktradersdaily.com
Arcturus Therapeutics Holdings Inc to Host Earnings Call - ACCESS Newswire
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $61.40 Average PT from Analysts - Defense World
Arcturus Therapeutics at Leerink’s Conference: mRNA Innovations and Strategic Plans - Investing.com UK
Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism - markets.businessinsider.com
Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group - Defense World
Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results - Simply Wall St
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo
HC Wainwright Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $60.00 - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Earns Overweight Rating from Cantor Fitzgerald - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript - Insider Monkey
Arcturus Therapeutics stock hits 52-week low at $14.3 By Investing.com - Investing.com Australia
Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock - Benzinga
Arcturus Therapeutics stock hits 52-week low at $14.3 - Investing.com India
Earnings call transcript: Arcturus Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com South Africa
Arcturus Therapeutics Reports Q4 2024 Earnings: EPS of ($1.11) M - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada
Arcturus Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Arcturus Therapeutics Holdings Inc earnings missed by $0.92, revenue fell short of estimates - Investing.com Canada
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):